CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MEISi is a small molecule developed by Meinox that targets critical proteins involved in noncommunicable diseases such as cancer, cardiovascular diseases, and diabetes. The project aims to create effective therapeutics to improve treatment options and reduce mortality rates associated with these diseases.
MEISi is the first innovative product of Meinox as a druggable substance, owing to its years of research on MEIS biology (published in prestigious journals like Nature and Cell Stem Cell, and PCT patented - pending national entry in 44 countries).
Meinox targets the deadliest noncommunicable diseases (NCDs); cancer, CVDs and diabetes, together accounting for nearly 71% of all deaths globally.
Never ending efforts and global targets in tackling these diseases show the importance of the developmen…
MEINOX ILAC TEKNOLOJILERI AS
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
